Actinogen Medical Raises $8.9 Million for Alzheimer’s Research

Actinogen Medical Limited (AU:ACW) has released an update.

Actinogen Medical Limited will strengthen its financial position with a capital increase of $8.9 million through a share placement and tender offer, with the aim of financing the ongoing XanaMIA trial for Alzheimer’s disease. The company has raised $5 million from experienced investors and expects up to $3.9 million from existing shareholders, with top-level executives and directors showing their confidence by participating in the raise. The capital raised will also support general working capital needs.

For more insight into AU:ACW stock, check out TipRanks’ Stock Analysis Page.